|Bid||0.1600 x 53590500|
|Ask||0.1650 x 50748300|
|Day's range||0.1600 - 0.1650|
|52-week range||0.0930 - 0.1950|
|Beta (5Y monthly)||3.07|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.31|
ImpediMed Limited ( ASX:IPD ) shareholders will doubtless be very grateful to see the share price up 33% in the last...
How far off is ImpediMed Limited ( ASX:IPD ) from its intrinsic value? Using the most recent financial data, we'll take...
ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to improve patient health, today launched "Lymphedema Can't," a healthcare initiative and communication campaign to educate breast cancer patients and survivors about the importance of early monitoring and intervention for lymphedema.